MSRD 100
Alternative Names: MSRD-100Latest Information Update: 28 Mar 2019
At a glance
- Originator Merz Pharmaceuticals
- Class Skin disorder therapies
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Atopic dermatitis
Most Recent Events
- 28 Mar 2019 No recent reports of development identified for clinical-Phase-Unknown development in Atopic-dermatitis in Germany (Topical, Gel)
- 08 Sep 2016 Merz Pharmaceuticals withdraws two phase III trials for Atopic dermatitis (In infants, In children, In adolescents, In adults) in USA (Topical, Gel) (NCT02677610; NCT02677636)
- 16 Feb 2016 Clinical trials in Atopic dermatitis in Germany (Topical) before February 2016